Read our latest updates & insights

Teva and Celltrion announce exclusive marketing deal under which Teva will commercialise Celltrion’s biosimilar rituximab and trastuzumab products in the US and CA.

Samsung application for SB3, biosimilar trastuzumab accepted for review by EMA.

FDA approves Amgen’s biosimilar to adalimumab, Amjevita™ (adalimumab-atto), 11 months after Amgen’s application was filed.

Brenzys®(SB4)  is the first biosimilar etanercept to be approved in Canada.

Pfizer terminates its relationship with Pfenex to develop PF582, biosimilar ranibizumab.

Brenzys® (SB4) becomes the first biosimilar etanercept to be approved in Australia.

EMA accepts Mylan/Biocon application for biosimilar pegfilgrastm for review.

FDA rejects Sandoz’s application for Zioxtenzo®, biosimilar pegfilgrastim.

Sandoz receives complete response letter from FDA relating to Zioxtenzo, Biosimilar pegfilgrastim, and is “working with the agency to address remaining questions.”

Samsung announces the EMA has accepted for its review its application for adalimumab biosimilar.